Loading...
Loading...
In a report published Monday, Jefferies reiterated its Buy rating on Neurocrine Biosciences
NBIX, and slightly raised its price target from $13.00 to $14.00.
Jefferies noted, “NBIX reported 4Q12 earnings per share and announced 2013 guidance. The next major catalyst for shares will be the data for ‘854 in movement disorders in May. We would be buyers ahead of these data and see significant upside potential as we can justify the entire valuation of NBIX on sales of elagolix for endometriosis.”
Neurocrine Biosciences closed on Friday at $10.84.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in